In conclusion, our study found that SIX4 promotes progression of osteosarcoma via upregulating IDH1 and metabolic reprogramming, which provides novel prognostic biomarkers and promising therapeutic targets for osteosarcoma patients. Here, SIX4 is linked to osteosarcoma.